{"id":47837,"date":"2025-09-07T00:54:26","date_gmt":"2025-09-06T17:54:26","guid":{"rendered":"https:\/\/hbbgroup.net\/kyoto-university-and-itochu-to-offer-low-cost-personalized-stem-cell-kits\/"},"modified":"2025-09-07T00:54:26","modified_gmt":"2025-09-06T17:54:26","slug":"kyoto-university-and-itochu-to-offer-low-cost-personalized-stem-cell-kits","status":"publish","type":"post","link":"https:\/\/hbbgroup.net\/zh\/kyoto-university-and-itochu-to-offer-low-cost-personalized-stem-cell-kits\/","title":{"rendered":"Kyoto University and Itochu to offer low-cost personalized stem cell kits"},"content":{"rendered":"<div data-trackable=\"article\">\n<div>\n<p><span><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\" data-dark-mode=\"false\">Pharmaceuticals<\/a><\/span><\/p>\n<p data-trackable=\"subhead\" data-dark-mode=\"false\">Kits to culture iPS cells used in cancer therapies will be offered at home and abroad<\/p>\n<\/div>\n<div>\n<p><img decoding=\"async\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F0%2F3%2F7%2F9%2F11439730-3-eng-GB%2Fc5e05b8c589c-photo_SXM2025090300003098-1-.jpg?width=780&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto\" alt=\"20250904N cell lab\" width=\"780\" height=\"auto\" loading=\"eager\"><\/p>\n<p data-trackable=\"caption\" data-dark-mode=\"false\">Researchers study stem cells at a recently opened facility run by Kyoto University&#8217;s Center for iPS Cell Research and Application. (Photo by Yuki Misumi)<\/p>\n<div>\n<p>YUI SATO and YUKI MISUMI<\/p>\n<div data-dark-mode=\"false\">\n<p><span>September 5, 2025 02:43 JST<\/span><\/p>\n<\/div>\n<\/div>\n<div>\n<div id=\"article-body-preview\" data-article-body data-trackable=\"bodytext\" data-atlas=\"body\">\n<p data-dark-mode=\"false\">TOKYO\/OSAKA &#8212; Kyoto University and Japanese trading house Itochu plan to release a kit as early as this year to aid in producing individualized stem-cell-based treatments from a patient&#8217;s own cells at low cost, Nikkei has learned.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div data-testid=\"article-footer\">\n<div data-article-type=\"News\">\n<div data-trackable=\"read-next-listing\" data-testid=\"read-next\">\n<p data-trackable=\"listing-title\">\n<h2>Read Next<\/h2>\n<\/p>\n<div>\n<ul>\n<div data-trackable=\"slot-1\">\n<li data-trackable=\"teaser-splash\">\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/sumitomo-pharma-files-for-approval-of-stem-cell-parkinson-s-treatment\" data-trackable=\"thumbnail\"><img fetchpriority=\"high\" decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/sumitomo-pharma-files-for-approval-of-stem-cell-parkinson-s-treatment\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F2%2F6%2F3%2F9%2F11349362-2-eng-GB%2F0cbdce594cad-20170127_iPS.jpg?width=700&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=394\" alt=\"Sumitomo Pharma files for approval of stem cell Parkinson's treatment\" width=\"700\" height=\"394\" loading=\"eager\"><\/a><\/p>\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\"><\/p>\n<p>Pharmaceuticals<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/sumitomo-pharma-files-for-approval-of-stem-cell-parkinson-s-treatment\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Sumitomo Pharma files for approval of stem cell Parkinson&#8217;s treatment<\/h4>\n<p><\/a><\/div>\n<\/li>\n<\/div>\n<div data-trackable=\"slot-2\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/science\" data-trackable=\"primary-tag\"><\/p>\n<p>Science<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/science\/japan-panel-oks-creating-human-fertilized-eggs-with-ips-cells-for-research\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Japan panel OKs creating human fertilized eggs with iPS cells for research<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/science\/japan-panel-oks-creating-human-fertilized-eggs-with-ips-cells-for-research\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/science\/japan-panel-oks-creating-human-fertilized-eggs-with-ips-cells-for-research\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F1%2F9%2F6%2F5%2F19395691-3-eng-GB%2FCropped-15504691430086904.jpg?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Japan panel OKs creating human fertilized eggs with iPS cells for research\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<div data-trackable=\"slot-3\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\"><\/p>\n<p>Pharmaceuticals<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-s-nikon-others-to-invest-675m-in-cutting-edge-drug-production\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Japan&#8217;s Nikon, others to invest $675m in cutting-edge drug production<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-s-nikon-others-to-invest-675m-in-cutting-edge-drug-production\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-s-nikon-others-to-invest-675m-in-cutting-edge-drug-production\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F3%2F9%2F2%2F7%2F49907293-3-eng-GB%2FCropped-1753706394photo_SXM2025072200001065.jpg?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Japan's Nikon, others to invest $675m in cutting-edge drug production\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<div data-trackable=\"slot-4\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\"><\/p>\n<p>Pharmaceuticals<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-drugmakers-aim-for-biopharma-surge-with-expanded-talent-pool\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Japan drugmakers aim for biopharma surge with expanded talent pool<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-drugmakers-aim-for-biopharma-surge-with-expanded-talent-pool\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-drugmakers-aim-for-biopharma-surge-with-expanded-talent-pool\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F3%2F3%2F5%2F5%2F49865533-4-eng-GB%2FCropped-1753105086photo.JPG?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Japan drugmakers aim for biopharma surge with expanded talent pool\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<div data-trackable=\"slot-5\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/biotechnology\" data-trackable=\"primary-tag\"><\/p>\n<p>Biotechnology<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/biotechnology\/samsung-biologics-pivots-to-contract-drugmaking-eyeing-40bn-market\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Samsung Biologics pivots to contract drugmaking, eyeing $40bn market<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/biotechnology\/samsung-biologics-pivots-to-contract-drugmaking-eyeing-40bn-market\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/biotechnology\/samsung-biologics-pivots-to-contract-drugmaking-eyeing-40bn-market\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F0%2F5%2F4%2F1%2F11431450-2-eng-GB%2Fe729249288fe-photo_SXM2025090100002085.jpg?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Samsung Biologics pivots to contract drugmaking, eyeing $40bn market\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<\/ul>\n<\/div>\n<\/div>\n<div data-trackable=\"latest-footer-listing\" data-test=\"latest-footer-listing\">\n<p data-trackable=\"listing-title\">\n<h2>Latest on Pharmaceuticals<\/h2>\n<\/p>\n<div>\n<div data-trackable=\"slot-1\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\"><\/p>\n<p>Pharmaceuticals<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/sumitomo-pharma-files-for-approval-of-stem-cell-parkinson-s-treatment\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Sumitomo Pharma files for approval of stem cell Parkinson&#8217;s treatment<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/sumitomo-pharma-files-for-approval-of-stem-cell-parkinson-s-treatment\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/sumitomo-pharma-files-for-approval-of-stem-cell-parkinson-s-treatment\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F2%2F6%2F3%2F9%2F11349362-2-eng-GB%2F0cbdce594cad-20170127_iPS.jpg?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Sumitomo Pharma files for approval of stem cell Parkinson's treatment\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<div data-trackable=\"slot-2\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\"><\/p>\n<p>Pharmaceuticals<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-s-nikon-others-to-invest-675m-in-cutting-edge-drug-production\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Japan&#8217;s Nikon, others to invest $675m in cutting-edge drug production<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-s-nikon-others-to-invest-675m-in-cutting-edge-drug-production\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-s-nikon-others-to-invest-675m-in-cutting-edge-drug-production\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F3%2F9%2F2%2F7%2F49907293-3-eng-GB%2FCropped-1753706394photo_SXM2025072200001065.jpg?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Japan's Nikon, others to invest $675m in cutting-edge drug production\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<div data-trackable=\"slot-3\">\n<li data-trackable=\"teaser-article\">\n<div><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\" data-trackable=\"primary-tag\"><\/p>\n<p>Pharmaceuticals<\/p>\n<p><\/a><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-drugmakers-aim-for-biopharma-surge-with-expanded-talent-pool\" data-trackable=\"headline\"><\/p>\n<h4 data-dark-mode=\"false\">Japan drugmakers aim for biopharma surge with expanded talent pool<\/h4>\n<p><\/a><\/div>\n<p><a href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-drugmakers-aim-for-biopharma-surge-with-expanded-talent-pool\" data-trackable=\"thumbnail\"><img decoding=\"async\" href=\"http:\/\/asia.nikkei.com\/business\/pharmaceuticals\/japan-drugmakers-aim-for-biopharma-surge-with-expanded-talent-pool\" src=\"https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F3%2F3%2F5%2F5%2F49865533-4-eng-GB%2FCropped-1753105086photo.JPG?width=178&#038;fit=cover&#038;gravity=faces&#038;dpr=2&#038;quality=medium&#038;source=nar-cms&#038;format=auto&#038;height=100\" alt=\"Japan drugmakers aim for biopharma surge with expanded talent pool\" width=\"178\" height=\"100\" loading=\"eager\"><\/a><\/p>\n<\/li>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Pharmaceuticals Kits to culture iPS cells used in cancer therapies will be offered at home and abroad Researchers study stem [&hellip;]<\/p>","protected":false},"author":1,"featured_media":47838,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95],"tags":[],"class_list":["post-47837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tin-tuc-the-gioi-vi"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/posts\/47837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/comments?post=47837"}],"version-history":[{"count":0,"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/posts\/47837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/media\/47838"}],"wp:attachment":[{"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/media?parent=47837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/categories?post=47837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbbgroup.net\/zh\/wp-json\/wp\/v2\/tags?post=47837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}